Gilead scraps a PhII/III study early as drug flops against ulcerative colitis
Just as Gilead $GILD was looking to buoy expectations in its R&D prospects, the big biotech had been hit with a setback on its late-stage pipeline. The company says it’s scrapping a Phase II/III ulcerative colitis study of its anti-MMP9 antibody GS-5745 after tracking insufficient efficacy to keep it in the clinic.
The Data Monitoring Committee made the call after reviewing the experiences of 150 patients in the study, which was supposed to recruit 1,600 patients altogether. Gilead signed off on the decision after agreeing with their conclusion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.